Table 2. Summary of the ADCs.
| antibody conjugates | conjugation method | linker configuration | linker-payload (payload) | ADC retention time in HIC (min) | DAR in HIC | aggregation in SEC (%) |
|---|---|---|---|---|---|---|
| trastuzumab | 5.8 | 0.4 | ||||
| ADC (5) | AJICAP | Exo-EVC | APL-1081 (MMAE) | 9.1 | 2.0 | 1.6 |
| ADC (6) | AJICAP | Exo-EEVC | APL-1091 (MMAE) | 8.7 | 2.0 | 1.4 |
| ADC (7) | AJICAP | Exo-EEVC | APL-1092 (Exatecan) | 8.0 | 2.0 | 1.0 |
| ADC (8) | interchainbreak | Exo-EEVC | APL-1091 (MMAE) | 11.3 | 7.8 | 0.5 |
| ADC (9) | interchainbreak | Exo-EEVC | APL-1092 (Exatecan) | 6.8 | 7.9 | 1.0 |
| ADC (10) | interchainbreak | linear-VC | Mc-VC-PAB-MMAE | 11.7 | 4.1 | 1.2 |
| ADC (11) | AJICAP | linear-VC | Mc-VC-PAB-MMAE | 10.8 | 1.9 | 1.8 |
| ADC (12) | AJICAP | linear-EVC | Mc-EVC-PAB-MMAE | 10.8 | 1.9 | 1.7 |
| T-Dxd | interchainbreak | linear-GGFG | Deruxtecan | 9.1 | 7.8 | 0.1 |